Without the phase III clinical trial, approvals for the Sinovac vaccine and other H5N1 vaccines are currently for production only, rather than direct vaccination.
When Yin Weidong, general manager of the vaccine developer Sinovac Biotech, established his company to develop a hepatitis A vaccine in 1992, he hadn't even heard the term 'biotech'.